Patient Support Services Welcome to the Berinert Expert Network (B.E.N®), a comprehensive assistance resource center for healthcare providers and their patients who depend on Berinert.

B.E.N. takes the hassle out of HAE therapy by:

  • Assisting you in starting your Berinert therapy
  • Working through insurance questions and issues
  • Connecting you with the HAE community
  • Enrolling you in support programs

*Peer supporters are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians.

Valuable assistance programs for patients

Save up to $12,000 in co-pays with the Berinert Co-Pay BENefit™

Living with HAE can be a heavy burden to bear. But it shouldn't also be a financial burden. Help take control of your HAE attacks and the cost of treatment. The Berinert Co-Pay BENefit* is a financial assistance program designed to cover your eligible out-of-pocket co-pay expenses—up to $12,000 per year.

Defend against loss of insurance with CSL Behring Assurance™

A gap in insurance shouldn't mean a gap in treatment. CSL Behring Assurance is designed to help ensure that people who rely on our therapies can continue to receive treatment even if they experience a lapse in third-party, private health insurance.

Patient Assistance program

Periodically, patients with chronic illnesses are faced with difficult insurance situations that may prevent access to life-sustaining therapies. To help ensure that patients receive the treatment they need, the Patient Assistance program provides medically necessary therapy to qualified individuals who are uninsured, underinsured, or unable to afford their prescribed therapy.

*The BERINERT Co-Pay Program is available for new or existing BERINERT patients. You must be a U.S. resident and insured in the U.S. Patients covered by state- or federally funded programs, such as Medicare, Medicaid, and Veterans Health Insurance, are NOT eligible.

The program cannot be used with any other rebate/coupon, free trial, or similar offer. Co-pay under the program is nontransferable. The program only applies in the United States and does not apply where prohibited by law, taxed, or restricted. CSL Behring reserves the right to rescind, revoke, or amend the program at any time without notice. Additional program restrictions may apply.

Save on Co-Pays: The Berinert Co-Pay BENefit™ may cover up to $12,000 of your eligible out-of-pocket expenses per year.

Download Enrollment Form »

B.E.N. P.A.L.S. are patient advocates who have experience with HAE and Berinert. They share their stories and help you understand your own Berinert therapy.

Home Support Services

Important Safety Information

BERINERT®, C1 Esterase Inhibitor (Human), is used in adults and children to treat swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat. The safety and efficacy of BERINERT in preventing HAE attacks have not been established.

Do not use BERINERT if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Inform your healthcare provider of all medications you are taking and of any medical conditions, especially any history of blood-clotting problems.

Blood clots have occurred in patients receiving BERINERT. Tell your healthcare provider if you have a history of heart or blood vessel disease, stroke, or blood clots, or if you have thick blood, an indwelling catheter/access device in a vein, or have been immobile for some time. Certain medications, such as birth control pills, may also increase your risk of clotting problems.

Report to your physician or an emergency room any signs and symptoms of a blood clot, including pain and/or swelling or discoloration of an arm or leg, with warmth over affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In addition, report immediately any signs or symptoms of allergic reactions to BERINERT, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

If you have been trained to self-administer BERINERT, immediately prepare the prescribed dose at the first symptoms of an attack. Seek immediate medical attention and do not begin to self-administer if an HAE attack has progressed to a point where you will be unable to prepare or administer a dose of BERINERT.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Call your doctor right away if swelling is not controlled after use of BERINERT.

In clinical studies, the most serious adverse reaction reported in subjects who received BERINERT was an increased severity of the pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received BERINERT than those receiving placebo was dysgeusia (a bad taste in mouth). Tell your healthcare provider about any side effect that bothers you or does not go away.

Because BERINERT is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for BERINERT, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

CSL Behring
© 2018 CSL Behring. The product information presented on this site is intended for US residents only. BRN/03-13-0059(1)d